Multiplex Assay Kit for Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay)

AT1R; AG2S; AG2-S; AGTR1A; AGTR1B; AT1; AT1B; AT2R1; AT2-R1; AT2R1A; AT2R1B; HAT1R; AT1 Receptor; Angiotensin Receptor 1B

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 79-97 91
EDTA plasma(n=5) 80-89 86
heparin plasma(n=5) 88-104 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-104% 78-94% 90-99% 79-96%
EDTA plasma(n=5) 89-98% 92-101% 78-103% 78-90%
heparin plasma(n=5) 94-102% 95-105% 79-91% 83-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:AGTR1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Journal of Atherosclerosis and Thrombosis Involvement of Angiotensin II Type 1 and 2 Receptors in Gelatinase ReCavia (Guinea pig )lation in Human Carotid Atheroma in vitro Pubmed:26947595
European Journal of Pharmaceutical Sciences Vitamin D3 potentiates the renoprotective effects of vildagliptin in a rat model of fructose/salt-induced insulin resistance Pubmed: 31866564
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: Role of AMPK/SIRT1 activation and DPP-4 inhibition Pubmed: 33108744
Fundam Clin Pharmacol Vitamin D3 potentiates the nephroprotective effects of vildagliptin‐metformin combination in a rat model of metabolic syndrome 34453360
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB658Hu02 Recombinant Angiotensin II Receptor 1 (AGTR1) Positive Control; Immunogen; SDS-PAGE; WB.
RPB658Hu03 Recombinant Angiotensin II Receptor 1 (AGTR1) Positive Control; Immunogen; SDS-PAGE; WB.
RPB658Hu01 Recombinant Angiotensin II Receptor 1 (AGTR1) Positive Control; Immunogen; SDS-PAGE; WB.
PAB658Hu01 Polyclonal Antibody to Angiotensin II Receptor 1 (AGTR1) WB; IHC; ICC; IP.
MAB658Hu22 Monoclonal Antibody to Angiotensin II Receptor 1 (AGTR1) WB; IHC; ICC; IP.
SEB658Hu ELISA Kit for Angiotensin II Receptor 1 (AGTR1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB658Hu Multiplex Assay Kit for Angiotensin II Receptor 1 (AGTR1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.